New drugs and regimens for tuberculosis

Kwok Chiu Chang, Eric Nuermberger, Giovanni Sotgiu, Chi Chiu Leung

Research output: Contribution to journalReview article

Abstract

Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public health threats worldwide. Although the last decade has witnessed advances in rapid diagnostic tools and use of repurposed and novel drugs for better managing drug-resistant TB, we need an appropriate TB control strategy and a well-functioning health infrastructure to ensure optimal operational use of rapid tests, judicious use of effective treatment regimens that can be rapidly tailored according to the drug resistance profile and timely management of risk factors and co-morbidities that promote infection and its progression to disease. We searched the published literature to discuss (i) standardized versus individualized therapies, including the choice between a single one-size-fit-all regimen versus different options with different key drugs determined mainly by rapid drug susceptibility testing, (ii) alternative regimens for managing drug-susceptible TB, (iii) evidence for using the World Health Organization (WHO) longer and shorter regimens for multidrug-resistant TB and (iv) evidence for using repurposed and novel drugs. We hope an easily applicable combination of biomarkers that accurately predict individual treatment outcome will soon be available to ultimately guide individualized therapy.

Original languageEnglish (US)
Pages (from-to)978-990
Number of pages13
JournalRespirology
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Multidrug-Resistant Tuberculosis
Drug Repositioning
Tuberculosis
Drug Resistance
Pharmaceutical Preparations
Fluoroquinolones
Rifampin
Disease Progression
Public Health
Biomarkers
Morbidity
Health
Therapeutics
Infection

Keywords

  • bedaquiline
  • clofazimine
  • delamanid
  • linezolid
  • pretomanid

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chang, K. C., Nuermberger, E., Sotgiu, G., & Leung, C. C. (2018). New drugs and regimens for tuberculosis. Respirology, 23(11), 978-990. https://doi.org/10.1111/resp.13345

New drugs and regimens for tuberculosis. / Chang, Kwok Chiu; Nuermberger, Eric; Sotgiu, Giovanni; Leung, Chi Chiu.

In: Respirology, Vol. 23, No. 11, 01.11.2018, p. 978-990.

Research output: Contribution to journalReview article

Chang, KC, Nuermberger, E, Sotgiu, G & Leung, CC 2018, 'New drugs and regimens for tuberculosis', Respirology, vol. 23, no. 11, pp. 978-990. https://doi.org/10.1111/resp.13345
Chang, Kwok Chiu ; Nuermberger, Eric ; Sotgiu, Giovanni ; Leung, Chi Chiu. / New drugs and regimens for tuberculosis. In: Respirology. 2018 ; Vol. 23, No. 11. pp. 978-990.
@article{ece8c3bf3f6e46a2bcc08ce2662a88bc,
title = "New drugs and regimens for tuberculosis",
abstract = "Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public health threats worldwide. Although the last decade has witnessed advances in rapid diagnostic tools and use of repurposed and novel drugs for better managing drug-resistant TB, we need an appropriate TB control strategy and a well-functioning health infrastructure to ensure optimal operational use of rapid tests, judicious use of effective treatment regimens that can be rapidly tailored according to the drug resistance profile and timely management of risk factors and co-morbidities that promote infection and its progression to disease. We searched the published literature to discuss (i) standardized versus individualized therapies, including the choice between a single one-size-fit-all regimen versus different options with different key drugs determined mainly by rapid drug susceptibility testing, (ii) alternative regimens for managing drug-susceptible TB, (iii) evidence for using the World Health Organization (WHO) longer and shorter regimens for multidrug-resistant TB and (iv) evidence for using repurposed and novel drugs. We hope an easily applicable combination of biomarkers that accurately predict individual treatment outcome will soon be available to ultimately guide individualized therapy.",
keywords = "bedaquiline, clofazimine, delamanid, linezolid, pretomanid",
author = "Chang, {Kwok Chiu} and Eric Nuermberger and Giovanni Sotgiu and Leung, {Chi Chiu}",
year = "2018",
month = "11",
day = "1",
doi = "10.1111/resp.13345",
language = "English (US)",
volume = "23",
pages = "978--990",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - New drugs and regimens for tuberculosis

AU - Chang, Kwok Chiu

AU - Nuermberger, Eric

AU - Sotgiu, Giovanni

AU - Leung, Chi Chiu

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public health threats worldwide. Although the last decade has witnessed advances in rapid diagnostic tools and use of repurposed and novel drugs for better managing drug-resistant TB, we need an appropriate TB control strategy and a well-functioning health infrastructure to ensure optimal operational use of rapid tests, judicious use of effective treatment regimens that can be rapidly tailored according to the drug resistance profile and timely management of risk factors and co-morbidities that promote infection and its progression to disease. We searched the published literature to discuss (i) standardized versus individualized therapies, including the choice between a single one-size-fit-all regimen versus different options with different key drugs determined mainly by rapid drug susceptibility testing, (ii) alternative regimens for managing drug-susceptible TB, (iii) evidence for using the World Health Organization (WHO) longer and shorter regimens for multidrug-resistant TB and (iv) evidence for using repurposed and novel drugs. We hope an easily applicable combination of biomarkers that accurately predict individual treatment outcome will soon be available to ultimately guide individualized therapy.

AB - Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public health threats worldwide. Although the last decade has witnessed advances in rapid diagnostic tools and use of repurposed and novel drugs for better managing drug-resistant TB, we need an appropriate TB control strategy and a well-functioning health infrastructure to ensure optimal operational use of rapid tests, judicious use of effective treatment regimens that can be rapidly tailored according to the drug resistance profile and timely management of risk factors and co-morbidities that promote infection and its progression to disease. We searched the published literature to discuss (i) standardized versus individualized therapies, including the choice between a single one-size-fit-all regimen versus different options with different key drugs determined mainly by rapid drug susceptibility testing, (ii) alternative regimens for managing drug-susceptible TB, (iii) evidence for using the World Health Organization (WHO) longer and shorter regimens for multidrug-resistant TB and (iv) evidence for using repurposed and novel drugs. We hope an easily applicable combination of biomarkers that accurately predict individual treatment outcome will soon be available to ultimately guide individualized therapy.

KW - bedaquiline

KW - clofazimine

KW - delamanid

KW - linezolid

KW - pretomanid

UR - http://www.scopus.com/inward/record.url?scp=85054636686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054636686&partnerID=8YFLogxK

U2 - 10.1111/resp.13345

DO - 10.1111/resp.13345

M3 - Review article

C2 - 29917287

AN - SCOPUS:85054636686

VL - 23

SP - 978

EP - 990

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 11

ER -